Isis licenses anti-inflammatory peptides to San Francisco startup
Rogne Bioscience, a privately-held biotechnology company based in San Francisco Bay Area, has acquired a licence to anti-inflammatory peptides from Oxford University Innovation.
We publish news of technology innovations, investment opportunities, together with updates from spin-out & start-up companies and licensees
Rogne Bioscience, a privately-held biotechnology company based in San Francisco Bay Area, has acquired a licence to anti-inflammatory peptides from Oxford University Innovation.
Oxford BioChronometrics was featured in a story in the Guardian “How your electronic DNA could be the secure login of the future."
Brainomix Ltd, a start-up from the Isis Software Incubator has been announced as a finalist in the ICT category of the Academic Enterprise Awards 2014.
The Isis Software Incubator, part of Oxford University Innovation, the University of Oxford’s technology commercialisation company, and City University London, have announced a new partnership.
Gene therapy specialist Oxford Biomedica has raised £20m to fund its portfolio of ophthalmology, CNS and cancer treatments.
Oxford University Innovation spin-out Oxford Immunotec has received a 2014 Queen’s Award for Enterprise.
OrganOx, a late-stage medical device company focused on increasing the quality and supply of organs for transplantation, has announced that it has closed a Series D Investment round.
A University of Oxford spin-out, OxSyBio, will develop 3D printing techniques to produce tissue-like synthetic materials for wound healing and drug delivery.
Next generation carbon nanomaterials such as graphene, carbon nanotubes and fullerenes, with their unique physical properties, have been hailed as “miracle materials”.